Why the FDA’s Politically Driven First-Ever Flavored-Vape Approval Almost Gets the Science Right
On May 5, the U.S. Food and Drug Administration (FDA) authorized four flavored e-cigarette pods—including the agency’s first-ever fruit flavors—from a small Los Angeles company called Glas. It is the biggest shift in the country’s tobacco harm reduction policy in a decade, and same-day reporting in The Wall Street Journal (WSJ) and POLITICO Pro tells the story of a decision that mostly tracks the science but was reached through a process that sidelined the scientists.
The Win for Tobacco Harm Reduction
Until now, the FDA had cleared only 39 vape products—all tobacco or menthol. The Glas decision opens the door to mango, blueberry, and two menthol pods for adults 21 and over. This finally aligns with the evidence: A 2020 JAMA Network Open study found that adults who took up non-tobacco-flavored e-cigarettes were more than twice as likely to quit smoking as those using tobacco flavors, with no matching jump in youth use. Population-level work in England similarly tied rising e-cigarette use to greater quit success.
How the Decision Was Actually Made
Despite research backing the harm reduction capacity of non-tobacco-flavored e-cigarettes, science did not drive the final outcome. WSJ reported that President Trump personally berated FDA Commissioner Marty Makary over the slow pace of flavored-vape approvals, citing the products’ importance to younger MAGA voters. POLITICO added that Makary had earlier blocked the Glas application even though career reviewers supported it. A former tobacco center director described the result as a politically driven reversal of a reversal that bypassed the agency’s scientific reviewers. That makes this a Pyrrhic win: A defensible answer reached by political pressure invites the next administration to reverse it just as easily.
A Clever Age-Gate with a Blind Spot
The authorization hinges on the technology Glas uses to keep teens from using their products; however, that technology—although effective as a gatekeeper—may hinder product uptake among the population that would benefit the most. The device requires government-ID verification, must be Bluetooth-paired to the verified user’s phone, and runs random biometric check-ins through a companion app. The acting tobacco center director described the system as potentially transformative for keeping flavored products away from minors.
On paper, it’s a reasonable trade for allowing flavors. In practice, it assumes a user who is happy installing apps, using Bluetooth, presenting their face on demand, and tolerating a vape that bricks itself when the phone dies. Older smokers. Research finds that older smokers, who carry the heaviest disease burden from cigarettes but adopt e-cigarettes at far lower rates than younger ones, prize ease of use over customization, often need help with basic Bluetooth pairing, and report low trust in digital health tools. A vape that fails a biometric check in dim light is exactly the friction this literature warns about.
The Price Problem
All that age-gating tech is expensive, too, which creates another barrier to switching—especially for those who are most likely to smoke and who face the most harms from smoking. Entry-level connected pod systems run $40-$70 and mid-tier ones $80-$150, versus $15-$25 for non-connected disposables. Glas sells its pods for $11.99 per pack and pairs them with its proprietary device. Each layer of mandated tech widens the price gap between the approved switching product and the cigarettes it is meant to displace.
That gap matters because U.S. smoking is increasingly concentrated among lower-income Americans. A large JAMA Internal Medicine analysis found a rise in smoking prevalence from about 14 percent among adults with no socioeconomic disadvantages (e.g., poverty, unemployment, low education, serious psychological distress) to 58 percent among those facing five or six disadvantages—and that gap is widening, not closing. Low-income smokers respond strongly to price when deciding whether to smoke at all, and a meta-analysis of e-cigarette price elasticity finds that e-cigarette demand is more price-elastic than cigarette demand: a 10 percent price hike cuts e-cigarette sales by about 11.5 percent. Choice experiments also show simple, cheap “cig-a-like” devices—not feature-rich connected ones—are most likely to replace cigarettes. A $50-$70 connected starter plus $12 pods is a manageable upgrade for a middle-class professional but a non-starter to a Medicaid-eligible smoker buying a $9 pack one at a time. Meanwhile, black-market disposables already make up roughly 70 percent of the e-cigarette market with no age verification required.
What a Mature Harm Reduction Policy Would Look Like
The Glas authorization is real progress. It accepts the cessation evidence on flavors, identifies a way to limit youth access without a blanket flavor ban, and shows a viable approval path for non-tobacco-affiliated companies. But allowing White House pressure to override career scientists corrodes the regulatory legitimacy that durable harm reduction policy depends on, and the very features that justified approval are calibrated to digitally fluent, higher-income users—not the older and lower-income smokers with the most to gain.
A mature framework would pair high-tech authorization with a parallel pathway for simpler, lower-cost reduced-risk products, recognizing that innovation in harm reduction shouldn’t be synonymous with smartphones and Bluetooth and that age-gating at the point of purchase (Tobacco 21) is working well to limit youth access to all nicotine products. Sens. Susan Collins (R-Maine) and Dick Durbin (D-Ill.) have warned that the flavors most available to kids are the ones kids gravitate toward. The unspoken corollary is that older smokers are deterred by whatever apps are required of them and that the smokers least able to afford a $70 connected starter kit are precisely the ones whose switching would deliver the largest health gains.